Valuation Madrigal Pharmaceuticals, Inc. Deutsche Boerse AG
Stocks
YDO1
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
23:55:01 21/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 440.50 EUR | -0.97% |
|
+0.85% | -11.05% |
Company Valuation: Madrigal Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,449 | 5,179 | 4,568 | 6,730 | 13,226 | 11,939 | - | - |
| Change | - | 257.45% | -11.79% | 47.33% | 96.52% | -9.73% | - | - |
| Enterprise Value (EV) 1 | 1,179 | 4,869 | 4,051 | 5,922 | 12,584 | 11,414 | 10,996 | 9,888 |
| Change | - | 313.04% | -16.81% | 46.21% | 112.48% | -9.29% | -3.67% | -10.07% |
| P/E | -5.79x | -16.8x | -11.6x | -14.1x | -45.3x | -81.8x | 82.1x | 22.8x |
| PBR | 7.15x | 26.6x | 11.3x | 9x | 22.1x | 26.6x | 14.6x | 7.19x |
| PEG | - | -0.9x | -0.7x | -1.48x | 1.1x | 1.6x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 37.4x | 13.8x | 7.82x | 5.57x | 4.09x |
| EV / Revenue | - | - | - | 32.9x | 13.1x | 7.48x | 5.13x | 3.38x |
| EV / EBITDA | -4.87x | -16.6x | -10.7x | -11.9x | -42.1x | -61.9x | 39.9x | 9.75x |
| EV / EBIT | -4.86x | -16.6x | -10.6x | -11.9x | -41.9x | -60.6x | 57.6x | 13.6x |
| EV / FCF | -4.87x | -16.6x | -12.4x | -13x | -66.2x | -56.9x | 40.4x | 12.3x |
| FCF Yield | -20.6% | -6.01% | -8.04% | -7.72% | -1.51% | -1.76% | 2.47% | 8.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.63 | -17.23 | -19.99 | -21.9 | -12.85 | -6.314 | 6.295 | 22.7 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 180.1 | 958.4 | 1,526 | 2,145 | 2,922 |
| EBITDA 1 | -242.1 | -293.1 | -380 | -496.8 | -298.6 | -184.3 | 275.3 | 1,014 |
| EBIT 1 | -242.5 | -293.6 | -380.5 | -497.9 | -300.1 | -188.3 | 190.7 | 726.9 |
| Net income 1 | -241.8 | -295.4 | -373.6 | -465.9 | -288.3 | -183.9 | 200 | 707.8 |
| Net Debt 1 | -269.9 | -309.5 | -517.5 | -807.7 | -642 | -524.5 | -943.2 | -2,051 |
| Reference price 2 | 84.74 | 290.25 | 231.38 | 308.57 | 582.34 | 516.74 | 516.74 | 516.74 |
| Nbr of stocks (in thousands) | 17,097 | 17,842 | 19,743 | 21,810 | 22,711 | 23,104 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | 26/02/25 | 19/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.45x | 7.54x | 15.37x | 1.38% | 72.12B | |
| 37.53x | 9.72x | 29.82x | 0.04% | 65.85B | |
| -18.08x | 7.59x | -9.85x | -.--% | 29.28B | |
| -79.5x | 14.86x | -71.64x | -.--% | 27.47B | |
| 33.76x | 6.66x | 17.64x | -.--% | 26.7B | |
| 27.2x | 5.1x | 17.12x | -.--% | 20.06B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.22B | |
| 2460.33x | 41.28x | -5047.29x | -.--% | 16.4B | |
| 16.73x | 4.96x | 11.58x | -.--% | 13.4B | |
| Average | 283.59x | 13.03x | -555.29x | 0.19% | 32.17B | |
| Weighted average by Cap. | 153.01x | 11.04x | -277.31x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MDGL Stock
- YDO1 Stock
- Valuation Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
